BioCurex, Inc.(fka BOCX)

[bocxman]

Road map for the year:

- Publishing in a peer-reviewed journal. Dr. Taketa will be publishing his data in the big industry journal soon ("Tumor Biology" or something). BOCX also needs to start publishing -- this is a PRIORITY and they are not on the ball in this regard. If we don't create a buzz among the medical community, our product is meaningless. Also, the medical community has many affluent and active investors and can contribute to the share price. Last but not least, the reporters/editors for CNN Health, PBS, and the other "pop medical" press outlets get their ideas from the industry journals.

- More news on Abbott. This is another biggy. I'd like to hear the company project some timelines, and lay out a concrete plan of attack to monetize their new partnership. The first thing we'll probably hear about is progress on the process of integrating RECAF onto ABT's proprietary ARCHITECT system. After this or even concurrently, we will probably hear about regulatory strategy. THIS IS THE BIG ONE. Nobody likes a pre-clinical biotech, and what's attractive here is that the regulatory path for a diagnostic is a cinche. Lots of questions to be answered in this regard, and believe me these questions will be answered soon. Will they choose to start with the prostate cancer indication, which is by far the largest market right now? If so, will they do a head-to-head against PSA or a combination trial or both?? OR, will they choose to start with lung cancer or breast cancer instead of prostate, since those are mega-markets that have no serum assay available for screening??? My prediction is that we start with a dual arm trial, RECAF plus PSA against PSA alone. Such a trial could be completed by Abbott in months, and compiling/submitting the data will take barely any time at all. There is a chance of course, that ABT will perform simultaneous trials for multiple indications. The cheap and simple regulatory process for a diagnostic makes the risk/reward attractive for simultaneous trials.
No question they are under a strict NDA, and we will never learn the details of the deal (standard industry practice), but you can be sure that the company can and will be providing updates.

- More healthcare conferences and investor conferences to get the word out and bring new strategic partnerships and investors aboard. I know for sure that the company will be on the conference circuit this year.

- Legitimate exchange listing. And I'm not talking about OTC-BB, although that is a step in the right direction. We are very close to meeting the AMEX "Standard 4" requirements. The requirements are a $3 share price, a $20 mil float, a $75 mil market cap, and 400 public shareholders with 1 mil shares publically held. As you can see, once BOCX reaches $3 we will be eligible for AMEX listing as our market cap will exceed $75 mil at that point and we meet all the other requirements currently. Yes, this requires a doubling of the current share price but this thing can make a move like that in one day. I don't think we'll be spending much time on the OTC-BB.

- More partnerships...we KNOW this will happen it's just a matter of when. The company used very strong language in the last 10-K, and clearly they can be believed when they say they are close to a deal.

- Progress and perhaps a partnership for the tumor imaging application of RECAF. This is a HUGE market and easy to get approval/penetrate kind of like diagnostics. The company was very direct in saying they will start focusing more energy in that direction (per recently filed 10-K). We need to get the market thinking about how important and VERSATILE this technology is. A licensing deal for therapeutic agent will also help in this regard, although it will take half a decade or more to monetize that so I'm more excited about imaging.

- A proper earnings call with a webcast. Of course there are no earnings to discuss but that's the same with 90% of biotechs. Upper management needs to stop being mysterious and start talking to shareholders. Aurelius says they are working on this and we can expect something soon.

Look guys, the cervical cancer P.R is better than nothing, but we have bigger fish to fry right now. MUCH bigger fish. The market yawned at the news, and so did I. If you're thinking the market yawned at the ABT news, you're wrong...our share price tripled based on that deal which is pretty good. All of us underestimated the overhead left over from trading our entire float over $2 last year. $2 is a formidable supply point and we simply couldn't surpass it...THIS TIME. Believe me we will eat that level for breakfast in the near future.